Updated ACC/AHA/HFSA 2022 guidelines on heart failure: what is new? From epidemiology to clinical management
Authors:
Open Access
- 23 April 2022
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 8 (5) , e23-e24
Abstract
The new 2022 guidelines on the management of heart failure (HF) have been recently published1 replacing those from 2013 and 2017. These guidelines reflect a collaboration between the American Heart Association (AHA), the American College of Cardiology (ACC), and the Heart Failure Society of America (HFSA), incorporating many recent studies, providing updated definitions and novel patient-centric and evidence-based recommendations on the management of HF.Keywords
Funding Information
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01-HL159062, R01-HL146691, T32-HL144456)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK123259, R01-DK033823)
- Diabetes Action Research and Education Foundation
- Monique Weill-Caulier Trust
- Irma T. Hirschl Trust
This publication has 5 references indexed in Scilit:
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesCirculation, 2022
- Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection FractionDiabetes Care, 2022
- Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine, 2021
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019